For research use only. Not for therapeutic Use.
Tesmilifene(CAT: I011418) is a novel small molecule that exhibits selective targeting of multiple-drug resistant (MDR) tumor cells. It works by sensitizing these resistant cells to chemotherapy, thereby enhancing the efficacy of chemotherapy treatments. Tesmilifene has shown potential clinical benefits in various tumor types and is being investigated in combination with different chemotherapeutic regimens. By overcoming drug resistance mechanisms in tumor cells, tesmilifene offers a promising approach to improve the effectiveness of chemotherapy and potentially enhance treatment outcomes in cancer patients.
| Catalog Number | I011418 |
| CAS Number | 98774-23-3 |
| Synonyms | 2-(4-benzylphenoxy)-N,N-diethyl-ethanamine;TESMILIFENE;N,N-Diethyl-2-(4-benzylphenoxy)ethanamine;DPPE;92981-78-7 (Hydrochloride);Depmpe;Ethanamine, N,N-diethyl-2-(4-(phenylmethyl)phenoxy)-;Unii-I43T3id6G2 |
| Molecular Formula | C19H25NO |
| Purity | ≥95% |
| Storage | RT |
| Overview of Clinical Research | Tesmilifene is an estrogen receptor antagonist and a histamine receptor antagonist. YM BioSciences terminates a worldwide pivotal phase III trial(DEC) in advanced breast cance in 2007. |
| IUPAC Name | 2-(4-benzylphenoxy)-N,N-diethylethanamine |
| InChI | InChI=1S/C19H25NO/c1-3-20(4-2)14-15-21-19-12-10-18(11-13-19)16-17-8-6-5-7-9-17/h5-13H,3-4,14-16H2,1-2H3 |
| InChIKey | NFIXBCVWIPOYCD-UHFFFAOYSA-N |
| SMILES | CCN(CC)CCOC1=CC=C(C=C1)CC2=CC=CC=C2 |
| Reference | 1: Raghavan D, Brandes LJ, Klapp K, Snyder T, Styles E, Tsao-Wei D, Lieskovsky G, Quinn DI, Ramsey EW. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J Urol. 2005 Nov;174(5):1808-13; discussion 1813. PubMed PMID: 16217292.<br /> |
